Novo Nordisk A/S (NVO) controlling shareholder Novo Holdings will receive a decision from European antitrust regulators on its proposed acquisition of Catalent (CTLT), by Dec. 6, Reuters reported on Monday, citing a European Commission filing.
The antitrust regulators can either allow the deal with or without modifications or launch a four-month investigation, Reuters reported.
Novo Holdings, Catalent, and the European Commission did not immediately reply to MT Newswires' requests for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 111.18, Change: -0.76, Percent Change: -0.67